ホーム>>Signaling Pathways>> Others>>Emixustat hydrochloride (ACU-4429 hydrochloride)

Emixustat hydrochloride (ACU-4429 hydrochloride) (Synonyms: ACU-4429 hydrochloride)

カタログ番号GC33763

エミクススタット塩酸塩 (ACU-4429 塩酸塩) は、232 ± の IC50 値で 11-cis-レチノール産生を強力に阻害します。 3nM。

Products are for research use only. Not for human use. We do not sell to patients.

Emixustat hydrochloride (ACU-4429 hydrochloride) 化学構造

Cas No.: 1141934-97-5

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$167.00
在庫あり
2mg
$101.00
在庫あり
5mg
$184.00
在庫あり
10mg
$295.00
在庫あり
50mg
$1,011.00
在庫あり
100mg
$1,609.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Emixustat hydrochloride strongly inhibits 11-cis-retinol production with IC50 values of 232 ± 3 nM. IC50 value: 232 nM [1]Target: 11-cis-retinolEmixustat hydrochloride is a novel visual cycle modulator, in healthy volunteers. Oral Emixustat was safe and well tolerated when administered once daily for 14 days with minimal systemic adverse events reported. Evaluation of emixustat in subjects with geographic atrophy associated with dry age-related macular degeneration.[2]

[1]. Kiser PD, et al. Catalytic mechanism of a retinoid isomerase essential for vertebrate vision. Nat Chem Biol. 2015 Jun;11(6):409-15. [2]. Kubota R, et al. Phase 1, dose-ranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers. Retina. 2014 Mar;34(3):603-9.

レビュー

Review for Emixustat hydrochloride (ACU-4429 hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Emixustat hydrochloride (ACU-4429 hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.